Literature DB >> 22332209

Success of intra-arterial chemotherapy (chemosurgery) for retinoblastoma: effect of orbitovascular anatomy.

Brian P Marr1, Crystal Hung, Yves P Gobin, Ira J Dunkel, Scott E Brodie, David H Abramson.   

Abstract

OBJECTIVES: To review results of orbital angiography performed during intra-arterial chemotherapy (chemosurgery) for treatment of retinoblastoma to assess the association of angiographic variability in orbitovascular anatomy with tumor response and outcomes.
METHODS: Medical records and 64 orbital angiograms were reviewed for 56 pediatric patients with retinoblastoma undergoing chemosurgery using a combination of melphalan hydrochloride, topotecan hydrochloride, or carboplatin. The major orbital arteries and capillary blush patterns were graded, and tumor response and recurrence were compared using the log-rank and Fisher exact tests.
RESULTS: Statistically significant variables for tumor response were lacrimal artery prominence (P = .001), previous treatment (P = .003), and lacrimal blush (P = .004). The only statistically significant variable for vitreous seed response was ciliary body blush (P = .03). Statistically significant variables influencing time to recurrence and time to enucleation were choroidal blush absence (P = .01) and lacrimal artery presence (P = .03), respectively.
CONCLUSIONS: The success of intra-arterial chemotherapy is dependent on delivery of drug to the target tumor within the eye via the ophthalmic artery. Because of the small volume of drug used (0.50-1.25 mL per treatment) and the selectivity of catheterization, variables affecting orbital blood flow greatly influence drug delivery and the success of chemosurgery.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22332209     DOI: 10.1001/archophthalmol.2011.386

Source DB:  PubMed          Journal:  Arch Ophthalmol        ISSN: 0003-9950


  4 in total

1.  The clinically used photosensitizer Verteporfin (VP) inhibits YAP-TEAD and human retinoblastoma cell growth in vitro without light activation.

Authors:  Katarzyna Brodowska; Ahmad Al-Moujahed; Anna Marmalidou; Melissa Meyer Zu Horste; Joanna Cichy; Joan W Miller; Evangelos Gragoudas; Demetrios G Vavvas
Journal:  Exp Eye Res       Date:  2014-05-15       Impact factor: 3.467

2.  Intra-Arterial Chemotherapy (Ophthalmic Artery Chemosurgery) for Group D Retinoblastoma.

Authors:  David H Abramson; Anthony B Daniels; Brian P Marr; Jasmine H Francis; Scott E Brodie; Ira J Dunkel; Y Pierre Gobin
Journal:  PLoS One       Date:  2016-01-12       Impact factor: 3.240

3.  Effects of metformin on retinoblastoma growth in vitro and in vivo.

Authors:  Katarzyna Brodowska; Sofia Theodoropoulou; Melissa Meyer Zu Hörste; Eleftherios I Paschalis; Kimio Takeuchi; Gordon Scott; David J Ramsey; Elizabeth Kiernan; Mien Hoang; Joanna Cichy; Joan W Miller; Evangelos S Gragoudas; Demetrios G Vavvas
Journal:  Int J Oncol       Date:  2014-09-11       Impact factor: 5.650

4.  Comparison of Intra-Arterial Chemotherapy Efficacy Delivered Through the Ophthalmic Artery or External Carotid Artery in a Cohort of Retinoblastoma Patients.

Authors:  Shichong Jia; Xuyang Wen; Min Zhou; Xiaoyu He; Minglei Han; Jiayan Fan; Renbing Jia; Xianqun Fan
Journal:  Front Med (Lausanne)       Date:  2021-06-11
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.